Discovery of Cysteine-targeting Covalent Protein Kinase Inhibitors von Lu, Xiaoyun, Smaill, Jeff B, Patterson, Adam V, Ding, Ke

Volltext

Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects von Lu, Xiaoyun, Chen, Hao, Patterson, Adam V, Smaill, Jeff B, Ding, Ke

Volltext

Design, Synthesis, and Biological Evaluation of Aminoindazole Derivatives as Highly Selective Covalent Inhibitors of Wild-Type and Gatekeeper Mutant FGFR4 von Shao, Min, Chen, Xiaojuan, Yang, Fang, Song, Xiaojuan, Zhou, Yang, Lin, Qianmeng, Fu, Ying, Ortega, Raquel, Lin, Xiaojing, Tu, Zhengchao, Patterson, Adam V, Smaill, Jeff B, Chen, Yongheng, Lu, Xiaoyun

Volltext

The feline skin microbiota: The bacteria inhabiting the skin of healthy and allergic cats von Older, Caitlin E, Diesel, Alison, Patterson, Adam P, Meason-Smith, Courtney, Johnson, Timothy J, Mansell, Joanne, Suchodolski, Jan S, Rodrigues Hoffmann, Aline

Volltext

The skin microbiome in healthy and allergic dogs von Rodrigues Hoffmann, Aline, Patterson, Adam P, Diesel, Alison, Lawhon, Sara D, Ly, Hoai Jaclyn, Elkins Stephenson, Christine, Mansell, Joanne, Steiner, Jörg M, Dowd, Scot E, Olivry, Thierry, Suchodolski, Jan S

Volltext

TAS‐120 Cancer Target Binding: Defining Reactivity and Revealing the First Fibroblast Growth Factor Receptor 1 (FGFR1) Irreversible Structure von Kalyukina, Maria, Yosaatmadja, Yuliana, Middleditch, Martin J., Patterson, Adam V., Smaill, Jeff B., Squire, Christopher J.

Volltext

Exploration of anomalous perceptual experiences in migraine between attacks using the Cardiff Anomalous Perceptions Scale von Shepherd, Alex J., Patterson, Adam J.K.

Volltext

Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes von Estrada-Bernal, Adriana, Le, Anh T, Doak, Andrea E, Tirunagaru, Vijaya G, Silva, Shevan, Bull, Matthew R, Smaill, Jeff B, Patterson, Adam V, Kim, Chul, Liu, Stephen V, Doebele, Robert C

Volltext

Structural Mechanism and Inhibitors Targeting EGFR Exon 20 Insertion (Ex20ins) Mutations von Chen, Hao, Hu, Shiliang, Patterson, Adam V., Smaill, Jeff B., Ding, Ke, Lu, Xiaoyun

Volltext

Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed von Yosaatmadja, Yuliana, Silva, Shevan, Dickson, James M., Patterson, Adam V., Smaill, Jeff B., Flanagan, Jack U., McKeage, Mark J., Squire, Christopher J.

Volltext

Nitroreductase gene-directed enzyme prodrug therapy: insights and advances toward clinical utility von Williams, Elsie M, Little, Rory F, Mowday, Alexandra M, Rich, Michelle H, Chan-Hyams, Jasmine V E, Copp, Janine N, Smaill, Jeff B, Patterson, Adam V, Ackerley, David F

Volltext

Tumour Hypoxia-Mediated Immunosuppression: Mechanisms and Therapeutic Approaches to Improve Cancer Immunotherapy von Fu, Zhe, Mowday, Alexandra M, Smaill, Jeff B, Hermans, Ian F, Patterson, Adam V

Volltext

Clostridium Bacteria: Harnessing Tumour Necrosis for Targeted Gene Delivery von Theys, Jan, Patterson, Adam V., Mowday, Alexandra M.

Volltext

What is living on your dog's skin? Characterization of the canine cutaneous mycobiota and fungal dysbiosis in canine allergic dermatitis von Meason-Smith, Courtney, Diesel, Alison, Patterson, Adam P., Older, Caitlin E., Mansell, Joanne M., Suchodolski, Jan S., Rodrigues Hoffmann, Aline

Volltext

Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506 von van der Wiel, Alexander M A, Jackson-Patel, Victoria, Niemans, Raymon, Yaromina, Ala, Liu, Emily, Marcus, Damiënne, Mowday, Alexandra M, Lieuwes, Natasja G, Biemans, Rianne, Lin, Xiaojing, Fu, Zhe, Kumara, Sisira, Jochems, Arthur, Ashoorzadeh, Amir, Anderson, Robert F, Hicks, Kevin O, Bull, Matthew R, Abbattista, Maria R, Guise, Christopher P, Deschoemaeker, Sofie, Thiolloy, Sophie, Heyerick, Arne, Solivio, Morwena J, Balbo, Silvia, Smaill, Jeff B, Theys, Jan, Dubois, Ludwig J, Patterson, Adam V, Lambin, Philippe

Volltext

Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials von Spiegelberg, Linda, Houben, Ruud, Niemans, Raymon, de Ruysscher, Dirk, Yaromina, Ala, Theys, Jan, Guise, Christopher P., Smaill, Jeffrey B., Patterson, Adam V., Lambin, Philippe, Dubois, Ludwig J.

Volltext

Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302 von Meng, Fanying, Evans, James W, Bhupathi, Deepthi, Banica, Monica, Lan, Leslie, Lorente, Gustavo, Duan, Jian-Xin, Cai, Xiaohong, Mowday, Alexandra M, Guise, Christopher P, Maroz, Andrej, Anderson, Robert F, Patterson, Adam V, Stachelek, Gregory C, Glazer, Peter M, Matteucci, Mark D, Hart, Charles P

Volltext

Discovery and optimization of 1-(1H-indol-1-yl)ethanone derivatives as CBP/EP300 bromodomain inhibitors for the treatment of castration-resistant prostate cancer von Xiang, Qiuping, Wang, Chao, Zhang, Yan, Xue, Xiaoqian, Song, Ming, Zhang, Cheng, Li, Chenchang, Wu, Chun, Li, Kuai, Hui, Xiaoyan, Zhou, Yulai, Smaill, Jeff B., Patterson, Adam V., Wu, Donghai, Ding, Ke, Xu, Yong

Volltext

Design, Synthesis, and Biological Evaluation of 5‑Formyl-pyrrolo[3,2‑b]pyridine-3-carboxamides as New Selective, Potent, and Reversible-Covalent FGFR4 Inhibitors von Yang, Fang, Chen, Xiaojuan, Song, Xiaojuan, Ortega, Raquel, Lin, Xiaojing, Deng, Wuqing, Guo, Jing, Tu, Zhengchao, Patterson, Adam V., Smaill, Jeff B., Chen, Yongheng, Lu, Xiaoyun

Volltext

Discovery of Isoform-Selective Akt3 Degraders Overcoming Osimertinib-Induced Resistance in Non-Small Cell Lung Cancer Cells von Xu, Fang, Zhang, Xin, Chen, Zhipeng, He, Sheng, Guo, Jing, Yu, Lei, Wang, Yongjin, Hou, Caiyun, AI-furas, Hawaa, Zheng, Zongyao, Smaill, Jeff B., Patterson, Adam V., Zhang, Zhi-Min, Chen, Liang, Ren, Xiaomei, Ding, Ke

Volltext